Q2 Earnings Estimate for RLMD Issued By HC Wainwright

Relmada Therapeutics, Inc. (NASDAQ:RLMD) – Analysts at HC Wainwright issued their Q2 2026 EPS estimates for Relmada Therapeutics in a research report issued to clients and investors on Thursday, June 18th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of ($0.23) for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Relmada Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Relmada Therapeutics’ Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($0.96) EPS, Q1 2027 earnings at ($0.22) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.28) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($0.85) EPS, FY2029 earnings at ($0.95) EPS and FY2030 earnings at ($0.32) EPS.

Several other research analysts have also recently issued reports on the stock. Mizuho raised their target price on shares of Relmada Therapeutics from $10.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, March 20th. Piper Sandler assumed coverage on shares of Relmada Therapeutics in a report on Tuesday, March 24th. They set an “overweight” rating and a $12.00 price target for the company. Finally, Lucid Cap Mkts raised shares of Relmada Therapeutics to a “strong-buy” rating in a research report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

Relmada Therapeutics Price Performance

Shares of Relmada Therapeutics stock opened at $6.73 on Monday. The business’s 50 day simple moving average is $7.00 and its two-hundred day simple moving average is $5.55. The stock has a market capitalization of $705.91 million, a P/E ratio of -6.17 and a beta of 0.39. Relmada Therapeutics has a one year low of $0.52 and a one year high of $8.00.

Relmada Therapeutics (NASDAQ:RLMD) last issued its earnings results on Tuesday, May 12th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.04).

Hedge Funds Weigh In On Relmada Therapeutics

Several hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC purchased a new position in shares of Relmada Therapeutics during the fourth quarter valued at about $35,041,000. Squadron Capital Management LLC purchased a new stake in Relmada Therapeutics in the fourth quarter worth about $32,361,000. Adage Capital Partners GP L.L.C. purchased a new stake in Relmada Therapeutics in the fourth quarter worth about $20,624,000. Spruce Street Capital LP bought a new stake in Relmada Therapeutics during the 4th quarter valued at approximately $19,736,000. Finally, Marshall Wace LLP boosted its position in Relmada Therapeutics by 1,072.4% during the 4th quarter. Marshall Wace LLP now owns 3,189,662 shares of the company’s stock valued at $15,406,000 after acquiring an additional 2,917,609 shares in the last quarter. 45.24% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Relmada Therapeutics

Here are the key news stories impacting Relmada Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Relmada Therapeutics and maintained a $12.00 price target, signaling continued analyst confidence in the stock’s longer-term upside. RLMD source
• Neutral Sentiment: The firm also published detailed earnings forecasts across 2026-2030, with losses expected to continue but gradually narrowing over time in some periods, which gives investors more visibility into the company’s path forward. RLMD source
• Neutral Sentiment: HC Wainwright’s FY2026 EPS estimate of -$0.96 is below the current consensus of -$0.75, suggesting the analyst expects heavier near-term losses than the market. RLMD source
• Negative Sentiment: Despite the bullish rating, the earnings estimates still show Relmada remains unprofitable for the foreseeable future, which can weigh on sentiment and limit upside until the company demonstrates better operating progress. RLMD source

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.